陇神戎发：子公司布瑞哌唑口溶膜临床试验获批

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trials of Brivaracetam, indicating ongoing development in the treatment of schizophrenia [1] - Clinical trials will continue following the approval, and the drug must undergo further evaluation and approval by the National Medical Products Administration before it can be manufactured and marketed [1]